Cargando…

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Manasa, Justen, Danaviah, Siva, Pillay, Sureshnee, Padayachee, Prevashinee, Mthiyane, Hloniphile, Mkhize, Charity, Lessells, Richard John, Seebregts, Christopher, de Wit, Tobias F. Rinke, Viljoen, Johannes, Katzenstein, David, De Oliveira, Tulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MyJove Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024245/
https://www.ncbi.nlm.nih.gov/pubmed/24747156
http://dx.doi.org/10.3791/51242
_version_ 1782316637638098944
author Manasa, Justen
Danaviah, Siva
Pillay, Sureshnee
Padayachee, Prevashinee
Mthiyane, Hloniphile
Mkhize, Charity
Lessells, Richard John
Seebregts, Christopher
de Wit, Tobias F. Rinke
Viljoen, Johannes
Katzenstein, David
De Oliveira, Tulio
author_facet Manasa, Justen
Danaviah, Siva
Pillay, Sureshnee
Padayachee, Prevashinee
Mthiyane, Hloniphile
Mkhize, Charity
Lessells, Richard John
Seebregts, Christopher
de Wit, Tobias F. Rinke
Viljoen, Johannes
Katzenstein, David
De Oliveira, Tulio
author_sort Manasa, Justen
collection PubMed
description HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical. Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described. The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method. Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel.
format Online
Article
Text
id pubmed-4024245
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MyJove Corporation
record_format MEDLINE/PubMed
spelling pubmed-40242452014-05-17 An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings Manasa, Justen Danaviah, Siva Pillay, Sureshnee Padayachee, Prevashinee Mthiyane, Hloniphile Mkhize, Charity Lessells, Richard John Seebregts, Christopher de Wit, Tobias F. Rinke Viljoen, Johannes Katzenstein, David De Oliveira, Tulio J Vis Exp Medicine HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical. Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described. The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method. Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel. MyJove Corporation 2014-03-30 /pmc/articles/PMC4024245/ /pubmed/24747156 http://dx.doi.org/10.3791/51242 Text en Copyright © 2014, Journal of Visualized Experiments http://creativecommons.org/licenses/by-nc/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License, which permits non-commercial use, distribution, and reproduction, provided the original work is properly cited.
spellingShingle Medicine
Manasa, Justen
Danaviah, Siva
Pillay, Sureshnee
Padayachee, Prevashinee
Mthiyane, Hloniphile
Mkhize, Charity
Lessells, Richard John
Seebregts, Christopher
de Wit, Tobias F. Rinke
Viljoen, Johannes
Katzenstein, David
De Oliveira, Tulio
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
title An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
title_full An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
title_fullStr An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
title_full_unstemmed An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
title_short An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
title_sort affordable hiv-1 drug resistance monitoring method for resource limited settings
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024245/
https://www.ncbi.nlm.nih.gov/pubmed/24747156
http://dx.doi.org/10.3791/51242
work_keys_str_mv AT manasajusten anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT danaviahsiva anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT pillaysureshnee anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT padayacheeprevashinee anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT mthiyanehloniphile anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT mkhizecharity anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT lessellsrichardjohn anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT seebregtschristopher anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT dewittobiasfrinke anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT viljoenjohannes anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT katzensteindavid anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT deoliveiratulio anaffordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT manasajusten affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT danaviahsiva affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT pillaysureshnee affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT padayacheeprevashinee affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT mthiyanehloniphile affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT mkhizecharity affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT lessellsrichardjohn affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT seebregtschristopher affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT dewittobiasfrinke affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT viljoenjohannes affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT katzensteindavid affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings
AT deoliveiratulio affordablehiv1drugresistancemonitoringmethodforresourcelimitedsettings